Hiroshima University is a Japanese national university located in Higashihiroshima and Hiroshima, Japan. Established in 1929, it was chartered as a university in 1949 following the merge of a number of national educational institutions.

During the past decade, Hiroshima University conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 1 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hiroshima University" #1 sponsor was "Hiroshima University" with 17 trials, followed by "Wakayama Medical University" with 4 trials sponsored, "Biogen" with 1 trials sponsored, "Children's Hospital of Philadelphia" with 1 trials sponsored and "Cleerly, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hiroshima University" #1 collaborator was "Unitika Ltd." with 2 trials as a collaborator, "Wakunaga Pharmaceutical Co., Ltd." with 2 trials as a collaborator, "Agency for Healthcare Research and Quality (AHRQ)" with 1 trials as a collaborator, "Agricultural Producers' Cooperative Corporation Shinpo-en" with 1 trials as a collaborator and "Biostir, Inc." with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Hiroshima University" are "Healthy" (4 trials), "Obesity" (3 trials), "Prediabetes" (3 trials), "Pancreatic Ductal Adenocarcinoma" (2 trials) and "Coronary Artery Disease" (1 trials). Many other conditions were trialed in "Hiroshima University" in a lesser frequency.

Most popular intervention types in "Hiroshima University" are "Dietary Supplement" (16 trials), "Drug" (5 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "200 mg of chrysanthemum flower oil" (1 trials), "300 mg of chrysanthemum flower oil" (1 trials), "400 mg of chrysanthemum flower oil" (1 trials) and "5-aminolevulinic acid phosphate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hiroshima University" are 19 trials for "All" genders, 4 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Hiroshima University". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Hiroshima University, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hiroshima University, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 17 trials that are defined as “Not Applicable".

Hiroshima University has several departments that took part in Clinical trials: "Hiroshima Rheumatology Clinic" - 3 trials, "Hiroshima University Hospital; Breast Surgery" - 3 trials, "Doi Clinic Internal Medicine Neurology" - 2 trials, "Hiroshima University Research Institute for Radiation Biology and Medicine Tumor Surgery" - 2 trials